Cells treated by in vitro fucosylation and methods of production and use thereof
US-9511095-B2 · Dec 6, 2016 · US
DNA-cell conjugates
US9327036B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9327036-B2 |
| Application number | US-201013263129-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2010 |
| Priority date | Apr 8, 2009 |
| Publication date | May 3, 2016 |
| Grant date | May 3, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides conjugates of DNA and cells by linking the DNA to a native functional group on the cell surface. The cells can be without cell walls or can have cell walls. The modified cells can be linked to a substrate surface and used in assay or bioreactors.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising: a live cell that has no cell wall, wherein the cell has a surface comprising a native functional group linked to a nucleic acid moiety, wherein the nucleic acid moiety is covalently linked directly to the native functional group, wherein the native functional group comprises an amino acid selected from the group consisting of lysine, cysteine, tyrosine, threonine, serine, aspartic acid, glutamic acid and tryptophan, and wherein the cell has not undergone metabolic engineering to introduce an azide modified sugar. 2. The composition of claim 1 , wherein the cell is a primary cell. 3. The composition of claim 1 , wherein the cell is a mammalian cell. 4. The composition of claim 1 , wherein the cell is a stem cell. 5. The composition of claim 1 , wherein the native functional group comprises lysine. 6. The composition of claim 1 , wherein the nucleic acid moiety comprises a member selected from the group consisting of an oligonucleotide, DNA, RNA, PNA and an aptamer. 7. The composition of claim 1 , wherein the nucleic acid moiety comprises single-stranded DNA. 8. The composition of claim 1 , wherein the nucleic acid moiety comprises from about 10 to about 200 nucleic acids. 9. The composition of claim 1 , wherein the nucleic acid moiety comprises an aptamer. 10. The composition of claim 1 , wherein the nucleic acid moiety comprises a linker. 11. The composition of claim 1 , comprising a mammalian cell comprising lysine on the cell surface; and a single-stranded deoxy-nucleic acid covalently linked to the lysine via an amide. 12. A composition comprising: a live cell that has no cell wall, wherein the cell has a surface comprising a native functional group linked to a nucleic acid moiety, wherein the native functional group comprises an amino acid selected from the group consisting of lysine, cysteine, tyrosine, threonine, serine, aspartic acid, glutamic acid and tryptophan, and the nucleic acid moiety is covalently linked to the native functional group. 13. The composition of claim 12 , wherein the cell is a primary cell. 14. The composition of claim 12 , wherein the cell is a mammalian cell. 15. The composition of claim 12 , wherein the cell is a stem cell. 16. The composition of claim 12 , wherein the native functional group comprises lysine. 17. The composition of claim 12 , wherein the nucleic acid moiety comprises a member selected from the group consisting of an oligonucleotide, DNA, RNA, PNA and an aptamer. 18. The composition of claim 12 , wherein the nucleic acid moiety comprises single-stranded DNA. 19. The composition of claim 12 , wherein the nucleic acid moiety comprises a linker. 20. The composition of claim 12 , comprising a mammalian cell comprising lysine on the cell surface; and a single-stranded deoxy-nucleic acid covalently linked to the lysine via an amide. 21. A composition comprising: a live cell that has no cell wall, wherein the cell has a surface comprising a native functional group linked to a nucleic acid moiety, wherein the native functional group comprises an amino acid, and the nucleic acid moiety is linked to the native functional group by a covalent bond formed by reaction with a primary amine of the native functional group.
Assignees
Inventors
Classifications
Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title
- C12N5/0006Primary
Modification of the membrane of cells, e.g. cell decoration · CPC title
- A61K47/48776Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9327036B2 cover?
- The present invention provides conjugates of DNA and cells by linking the DNA to a native functional group on the cell surface. The cells can be without cell walls or can have cell walls. The modified cells can be linked to a substrate surface and used in assay or bioreactors.
- Who is the assignee on this patent?
- Hsiao Shih-Chia, Francis Matthew B, Bertozzi Carolyn, and 7 more
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0006. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).